The Ultimate Guide To Proteinuria Therapeutics Market 2019-2023
The report provides a detailed analysis of the market by product and geography. Also, the proteinuria therapeutics market forecast report analyzes the market's competitive landscape and offers information on several market vendors.
Market Competitive Analysis
The proteinuria therapeutics market is fragmented, and the degree of fragmentation will increase during the forecast period. With the rising kidney related diseases and other health issues, vendors and governmental bodies are taking efforts to increase awareness about various kidney diseases along with proteinuria. AbbVie Inc., AstraZeneca Plc, and Boehringer Ingelheim International GmbH are some of the major market participants. Though the accelerating growth momentum will offer immense growth opportunities, the lack of curative therapies will challenge the growth of the market participants. To make the most of the opportunities, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.
The report provides information on the production, sustainability, and prospects of several companies, including:
AbbVie Inc.
AstraZeneca Plc
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Co.
Merck & Co. Inc.
Novartis AG
Pfizer Inc.
Sanofi
Takeda Pharmaceutical Co. Ltd.
Teva Pharmaceutical Industries Ltd.
Proteinuria Therapeutics Market: Key Drivers and Trends
The prevalence of proteinuria increases with age and the rapid advances in healthcare and the availability of advanced treatment options have increased the life expectancy of people, leading to a rise in the geriatric population. This will result in an increase in number of proteinuria cases, driving the need for effective therapeutics. Considering the potential usage of proteinuria, vendors are focusing on developing novel therapies to reduce proteinuria.
Moreover, proteinuria is also common among people with a history of renal diseases. Proteinuria can also be caused by diseases such as multiple myeloma, AIDS, lupus, and rheumatoid arthritis. The prevalence of these risk factors will also drive the need for proteinuria therapeutics over the forecast period.
Proteinuria Therapeutics Market: Segmentation by Region
North America is a major market for proteinuria therapeutics. The growing sales of off-label drugs and the increasing prevalence of various associated risk factors for proteinuria are driving market growth in the region. The high prevalence of the risk factors for proteinuria is also increasing the adoption of therapeutics for its treatment.
During the forecast period, over 51% of the overall market growth will originate from North America. However, market growth in this region will be slower than the growth of the market in Asia.
Increasing prevalence of associated risk factors will drive the proteinuria therapeutics market
The rapid developments in the healthcare industry and the availability of advanced treatment options have led to a significant increase in the life expectancy of people, which has resulted in the rise in the geriatric population. The prevalence of proteinuria increases with age, hence, the rise in the geriatric population is increasing the number of proteinuria cases. Moreover, proteinuria can also be caused by diseases such as multiple myeloma, AIDS, lupus, and rheumatoid arthritis. This is increasing the need for effective therapeutics, which is encouraging vendors to focus on developing novel therapies to treat proteinuria.
Introduction of smartphone-based diagnosis and treatment – An emerging trend in the osteoporosis market
The introduction of smartphone-based diagnosis and treatment is identified as one of the key proteinuria therapeutics market trends. Technological advancements help in increasing the adherence to treatment. The introduction of smartphone-based applications helps in effective and quick results at lower costs. These applications do not need a specialist to make clinical decisions as they are fully autonomous. Such advancements will help patients to identify proteinuria and enable nephrologists to provide effective treatment.